Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Febrile seizures Indication Strategy Report 2026: SCN1A, Trials and Deals
23 July 2026
2026 Febrile seizures strategy: epidemiology, SCN1A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Status epilepticus Indication Strategy Report 2026: GABA-A receptor, Trials and Deals
23 July 2026
2026 Status epilepticus strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Focal epilepsy Indication Strategy Report 2026: SV2A, Trials and Deals
23 July 2026
2026 Focal epilepsy strategy: epidemiology, SV2A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…
Latest Hotspot
8 min read
Temporal lobe epilepsy Indication Strategy Report 2026: SV2A, Trials and Deals
23 July 2026
2026 Temporal lobe epilepsy strategy: epidemiology, SV2A biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Absence epilepsy Indication Strategy Report 2026: CACNA1H, Trials and Deals
23 July 2026
2026 Absence epilepsy strategy: epidemiology, CACNA1H biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized…
Latest Hotspot
8 min read
Allergic bronchopulmonary aspergillosis Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Allergic bronchopulmonary aspergillosis strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Chronic eosinophilic pneumonia Indication Strategy Report 2026: IL-5, Trials and Deals
23 July 2026
2026 Chronic eosinophilic pneumonia strategy: epidemiology, IL-5 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Dermatitis herpetiformis Indication Strategy Report 2026: TG2, Trials and Deals
23 July 2026
2026 Dermatitis herpetiformis strategy: epidemiology, TG2 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Undifferentiated connective tissue disease Indication Strategy Report 2026: IFNAR1, Trials and Deals
23 July 2026
2026 Undifferentiated connective tissue disease strategy: epidemiology, IFNAR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Mixed connective tissue disease Indication Strategy Report 2026: IFNAR1, Trials and Deals
23 July 2026
2026 Mixed connective tissue disease strategy: epidemiology, IFNAR1 biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Microscopic polyangiitis Indication Strategy Report 2026: C5aR, Trials and Deals
23 July 2026
2026 Microscopic polyangiitis strategy: epidemiology, C5aR biology, clinical competition, recent deals, unmet need and market attractiveness.
Latest Hotspot
8 min read
Granulomatosis with polyangiitis Indication Strategy Report 2026: C5aR, Trials and Deals
23 July 2026
2026 Granulomatosis with polyangiitis strategy: epidemiology, C5aR biology, clinical competition, recent deals, unmet need and market attractiveness.